In rare slip, Pfizer steamroller Ibrance fails to show it helps patients live longer
admin 25th June 2018 Uncategorised 0More than two years ago, Pfizer’s Ibrance won an FDA nod to treat some breast cancer patients whose disease progressed after endocrine therapy. But new study results suggest the drug may not actually help those patients live longer.
More: In rare slip, Pfizer steamroller Ibrance fails to show it helps patients live longer
Source: fierce